Breast Cancer

Published Date : Sep 2023
Category : Oncology
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

Beyond the Statistics: The Human Toll of Rising Breast Cancer Incidence

The rising incidence of breast cancer worldwide is a matter of growing concern, reflecting the urgent need for proactive healthcare interventions. As breast cancer rates continue to climb, that is surprising as per BCRF reports, in 2020, there were 2.3 million women diagnosed with breast cancer and 685,000 deaths globally which places a substantial burden on healthcare payers and systems.

Effectively managing breast cancer is crucial for improving patient outcomes worldwide because, as per the Breast cancer statistics report, female breast cancer has now surpassed lung cancer as the most commonly diagnosed cancer. As it accounts for 12.5% of all new annual cancer cases worldwide, making it the most common cancer in the world, and therefore to ensure the sustainability of healthcare resources and the well-being of affected individuals proper management has become a need.

An estimated report by WHO states that 2,261,419 new cases of breast cancer were diagnosed in women across the world in 2020 which brought major concern for healthcare providers to reshape the landscape of Breast Cancer Management.

Breast cancer is a type of cancer that begins in the breast cells. It is one of the most prevalent and well-known forms of cancer affecting women, although it also occurs in men, but less frequently. This disease develops when the cells in the breast begin to grow uncontrollably, forming a tumor that invades surrounding tissues and potentially spreads to other parts of the body through the bloodstream or lymphatic system.

Breast cancer is a complex and diverse disease, with various subtypes that have distinct characteristics and treatment approaches. It occurs in different parts of the breast, including the milk ducts (ductal carcinoma) and the lobules (lobular carcinoma), which are the glandular structures responsible for milk production.

Breast cancer has combinations of symptoms, especially when it is more advanced. Most females do not experience any symptoms when the cancer is still early.

Symptoms of breast cancer mostly include a breast lump or thickening, often without pain, and a change in the size, shape, or appearance of the breast. Dimpling, redness, pitting, or other changes in the skin, change in nipple appearance surrounding the nipple (areola), and abnormal or bloody fluid from the nipple are major symptoms observed in patients.

Additionally, breast cancer is categorized based on the presence or absence of specific receptors, such as estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2), which guide treatment decisions.

As per BCRF reports, Breast cancer is the most common cancer in women overall. In 140 of the 184 nations worldwide, it is the type of cancer that women are most likely to develop. At of the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the past 5 years, making it the world’s most prevalent cancer.

Breast cancer occurs in every country of the world in women at any age after puberty but with increasing rates in later life Breast cancer is the most common cancer among American women. There are more than 4 million breast cancer survivors in the United States, including women still being treated and those who have completed treatment as per the American Cancer Society.

As per NIH, Female breast cancer is the fight most common cause of mortality in the world. Around the world, 684,996 women are expected to die from breast cancer in 2020.

Therefore, early detection is a critical factor in improving the outcomes for individuals with breast cancer. Regular breast examinations, clinical breast examinations, and mammography screenings are essential tools in identifying the disease at an early, more treatable stage.

Additionally, advances in diagnostic techniques, genetic testing, and personalized treatment approaches have revolutionized the management of breast cancer and have been identified as an important element of expanding the marketplace on a global scale for industry players. As a result, it contributes to the globalization of developing products.

Breast cancer is a complex and multifaceted disease that affects millions of people worldwide. Efforts in research by market players, search for early detection techniques, and treatments have continued to evolve and grow, offering hope for improved and significant survival rates and enhanced quality of life for those affected by cancer.

The present condition of the breast cancer disease market is propelling industries in the right direction and providing emerging opportunities for a variety of market giants in combatting this formidable disease.

Advancements in Early Detection of Breast Cancer is A Lifesaving Revolution for Patients Outcomes

Diagnosis Analysis

As per U.S. breast cancer (BC) statistics, it is the most commonly diagnosed cancer among U.S. women. About 30% of all newly diagnosed cancers in women each year are breast cancer.

Diagnosing BC involves a combination of medical history evaluation, physical examination, specific diagnostic blood tests, biopsy, and necessary surgeries along with the essential therapies for better outcomes. There are several diagnostic methods and tests used to detect breast cancer in women. These methods serve different purposes in the diagnostic process.

Here are various types of diagnostic methods used to detect breast cancer:

  1. Clinical Breast Examination (CBE):

A physical examination of the breasts is conducted by a healthcare provider to detect lumps, changes, or abnormalities in the breast.

  1. Imaging Studies-

  • Mammography: A common screening method that uses X-rays to create detailed images of the breast tissue. Mammography detects tumors or abnormalities that are too small to feel.
  • Breast Self-Examination (BSE): A simple self-examination in which women examine their breasts for any lumps, or changes in size, shape, or texture. While not a diagnostic tool, it helps in detecting abnormalities.
  • Breast Ultrasound: This type of imaging technique is based on High-frequency sound waves used to create images of the breast. It helps to determine whether a lump is solid (potentially cancerous) or fluid-filled (likely a cyst).
  • Breast MRI (Magnetic Resonance Imaging): MRI is most commonly used to detect breast cancer and MRI uses magnetic fields and radio waves to create detailed images of the breast. It's often used in high-risk individuals or to further evaluate abnormalities found in other tests.
  1. Biopsy-

The definitive method for diagnosing breast cancer is biopsy. It involves removing a sample of tissue from the breast for examination. There are various types of breast biopsies which include:

  • Fine Needle Aspiration (FNA): This type of biopsy uses a thin, hollow needle to remove cells or a small tissue sample from the breast to detect abnormalities.
  • Core Needle Biopsy: This type of biopsy involves the use of a larger, hollow needle to extract a small core of tissue and identify the stage of breast cancer.
  • Vacuum-Assisted Biopsy: This type involves a specialized vacuum device used to remove a larger tissue sample and eliminate the higher chance of infection spreading in the breast.
  • Stereotactic Biopsy: X-ray or mammogram guidance is used to precisely target and remove tissue by not harming the other areas and healthy tissues.
  • Ultrasound-Guided Biopsy: Ultrasound imaging helps guide the needle to the target area.
  1. Genetic Testing-

  • BRCA Testing: Genetic testing for BRCA1 and BRCA2 mutations helps in identifying individuals at higher risk of developing breast cancer. For instance, Color Genomics and Quest Diagnostics have made high-tech advances in genetics test kits that focus on BRCA1 and BRCA2 mutations, providing information about an individual's risk of hereditary breast and ovarian cancer.

Emerging Technologies Used for the Detection of Breast Cancer

  • Liquid Biopsy: This type of biopsy is an emerging technology that detects cancer-related biomarkers, such as circulating tumor DNA (ctDNA), in a blood sample. While this is not yet a primary diagnostic tool considered for use, it's being researched for its potential in monitoring treatment response and detecting cancer recurrence.
  • Multigene Panel Testing and Ductal Lavage and Nipple Aspiration: These Comprehensive genetic testing kits and panels assess multiple genes associated with breast cancer risk and specialized techniques that collect fluid from the breast ducts for analysis. These methods are used in research and in the near future may help to identify high-risk individuals.

Additionally, market players have engaged in significant collaborations and deals to expand their capabilities and bring innovative solutions to the breast cancer market. For instance, pharmaceutical companies collaborate with diagnostic laboratories to develop companion diagnostics for their targeted therapies. These partnerships have ensured that patients who will benefit most from specific detection and treatments are identified accurately.

The below table provides names of the market competitors who are transforming healthcare with advanced diagnostic breakthroughs, are listed below

                                                                                        Market Players of Diagnostic Devices

Imaging Studies


Genetic Testing

Hologic, Inc.

Cook Medical, Inc

Myriad Genetics, Inc

GE Healthcare

Siemens Healthineers

Invitae Corporation

Siemens Healthineers

PerkinElmer, Inc.

Ambry Genetics

Philips Healthcare

Philips Healthcare

Quest Diagnostics

Toshiba Medical Systems

BARD Biopsy Systems

Color Genomics, Inc

Hitachi Healthcare Americas

Philips Healthcare


Planmed Oy

GE Healthcare


Aurora Imaging Technology, Inc



Fujifilm Medical Systems

Devicor Medical Products, Inc.


Agfa-Gevaert Group




                                                                                         Diagnostic Product Names

Imaging Studies


Genetic Testing

Ingenia 3.0T MRI with Breast Exam

InSet™ II Soft Tissue Biopsy System

AmbryScore for Breast Cancer

Celesteion PET/CT System

Mammotome® Breast Biopsy Systems

Color Hereditary Cancer Test

Echelon Oval 1.5T MRI

Xpert® UltraPath™ System


Planmed Clarity 2D and 3D Digital Mammography System

Ingenia 3.0T Breast MRI

Invitae Breast Cancer Multi-Gene Panel

Aurora Breast MRI

GE Breast Suite


DR 800 Digital Mammography Solution

Magnetom Aera Breast Dot Engine


ASPIRE Cristalle Mammography System



MAMMOMAT Revelation Mammography System

Affirm Prone Biopsy System


ACUSON S2000 Automated Breast Volume Scanner (ABVS)




These diagnostic methods are essential for detecting breast cancer, determining its type and stage, and guiding further treatment decisions. The choice of diagnostic tests depends on factors like the patient's age, risk factors, symptoms, and the results of earlier tests. Early detection through regular screening and prompt evaluation of abnormalities is key to improving breast cancer outcomes.

DiseaseLandscape Insights works with the market leader to establish and design the right approach towards various diagnostic kits, by making use of cutting-edge technology to improve the current diagnostic strategy and support players in providing data on current market participants and their products that help them to recognize market dynamics. By using DLI's services, stakeholders are able to direct the path of their company's management and implement market expansion plans.

Treatment Analysis

There are many treatment options for BC available in the market. By analyzing the type of cancer and other factors of the individual patient’s body type and the severity of the infection the treatment is given.

  1. Surgery:

    The various disorders and infections that occur in breast tissues are treated with medication, surgery, and chemotherapy which involves receiving various types of therapy. BC treated by surgery requires special or additional care.
  • Lumpectomy (Breast-Conserving Surgery): This surgery is commonly used and involves removing the tumor and a small margin of healthy tissue, preserving the breast.
  • Mastectomy: This procedure involves removing the entire breast. There are different types of mastectomies, including Simple or total mastectomy and modified radical mastectomy, Skin-sparing mastectomy, Nipple-sparing mastectomy this surgery is difficult to perform but is highly used and recommended for patients with higher risk and for the last stage of cancer.
  1. Radiation Therapy:

  • External Beam Radiation: High-energy beams are directed at the breast to kill cancer cells
  • Internal Radiation (Brachytherapy): Radioactive implants are placed directly in or near the tumor site
  • Intraoperative Radiation Therapy (IORT): Radiation is delivered during surgery.
  1. Targeted Therapy:

  • HER2-Targeted Therapy: For HER2-positive breast cancer, drugs like Trastuzumab (Herceptin) and Pertuzumab are used to treat breast cancer.
  • CDK4/6 Inhibitors: Drugs like Palbociclib, Ribociclib, and Abemaciclib are used in combination with hormone therapy for certain breast cancers.
  • PARP Inhibitors: Olaparib and Talazoparib are used for breast cancers with specific genetic mutations, like BRCA mutations. This also involves the use of genetic testing to identify the BRCA mutations.
  1. Chemotherapy:

Chemotherapy Drugs: Medications, either oral or intravenous, are used to kill or slow the growth of cancer cells. Combinations of chemotherapy drugs are often used. As per WHO, the chemotherapy drugs available today are very effective in decreasing the chances of cancer spread or recurrence of dangerous cell growth and are generally given as outpatient therapy.

Additionally, biological agents like HER-2/neu oncogene and HER-2 positive are very effective treatments used but are very expensive to administer, because they are antibodies rather than chemicals. When these targeted biological therapies are given to patients, they are combined with chemotherapy drugs to make them effective at killing cancer cells.

Emerging Treatments for Breast Cancer

  • Immunotherapy: Immune Checkpoint Inhibitors: Pembrolizumab and Atezolizumab are being studied in clinical trials for certain breast cancers, especially triple-negative breast cancer
  • Adjuvant and Neoadjuvant Therapy: Adjuvant therapy is given after surgery to reduce the risk of cancer recurrence. Neoadjuvant therapy is given before surgery to shrink tumors, making surgery more effective.
  • Hormone Therapy like Selective Estrogen Receptor Modulators (SERMs): Drugs like Tamoxifen block the effects of estrogen on breast cancer cells.
  • Aromatase Inhibitors: These drugs, such as Anastrozole and Letrozole, reduce the production of estrogen in postmenopausal women.

The below table shows the market leaders who are rebuilding the landscape and encouraging innovation to improve health outcomes by expanding the treatment options for common and serious diseases like Breast Cancer.

                                                                     Market Players in the Treatment of Breast Cancer


Targeted Therapy

Radiation Therapy













Johnson & Johnson

Eli Lilly


Leica Biosystems



BD - Becton, Dickinson, and Company






Targeted Therapy

Radiation Therapy

StealthStation™ S8 Surgical Navigation System



LOCalizer™ Surgical Guidance System



Mammotome® Breast Biopsy System



ATEC® Breast Biopsy System



Sage™ Breast Biopsy Site Identification System







"Modelling the Future: Advances in Breast Cancer Care Market Trends and Administration"

Market Trends Analysis

Market trends in breast cancer are shaped by a combination of factors, including advancements in technology, evolving treatment paradigms, and a growing emphasis on early detection and personalized care. Notable market players have played a significant role in setting trends that drive innovation and improvements in breast cancer diagnosis and treatment.

One prominent trend is the increasing emphasis on early detection and screening. Mammography, which is the standard option for breast cancer screening, has now evolved with the introduction of 3D mammography (tomosynthesis), improving the accuracy of breast cancer detection.

Market leaders have invested in research and development to enhance imaging technologies, making early diagnosis more effective and accessible.

Additionally, the rise of genetic testing is another notable trend. Companies have developed comprehensive genetic testing panels, enabling a deeper understanding of a patient's cancer profile and potential treatment options. This trend aligns with the growing interest in personalized medicine, where treatment decisions are guided by the molecular characteristics of the tumor.

Along with other trends, Immunotherapy has emerged as a game-changing trend in breast cancer treatment. Market leaders have conducted extensive research to develop immunotherapies, including checkpoint inhibitors, to treat certain subtypes of breast cancer, such as triple-negative breast cancer. These therapies harness the body's immune system to target and destroy cancer cells, offering new hope for patients with challenging-to-treat cancers.

Partnerships and collaborations between pharmaceutical companies, research institutions, and healthcare providers have accelerated research, drug development, and clinical trials. This collaborative trend has fostered innovation and accelerated the translation of discoveries into effective treatments, ultimately benefiting breast cancer patients.

Overall, market trends in breast cancer reflect a dynamic landscape with a focus on early detection, personalized care, and improved patient outcomes. Notable market players have been pivotal in driving these trends, with a commitment to innovation in breast cancer care.

DiseaseLandscape Insights DLI provides clients with an extensive understanding of industry trends and assists market players with a data-driven strategy, enabling them to make wise strategic decisions.

DLI successfully navigates changes and grabs opportunities for market players in the healthcare industry by decoding shifts in demand, technology, and laws, ensuring that customers stay ahead in a constantly shifting environment.

A Comprehensive Approach by Market Players for Addressing the Global Rise in Breast Cancer Cases"

Competitive Analysis

Competitive analysis in the breast cancer market involves assessing the strategies, products, and innovations of key market players. The breast cancer market is highly competitive, with pharmaceutical companies, medical device manufacturers, diagnostic laboratories, and research institutions vying for prominence.

Here's an overview of the competitive landscape and notable deals by market players:

The development and marketing of targeted medicines for breast cancer have been greatly assisted by pharmaceutical giants for instance,

  • Roche, Pfizer, and Novartis treatment patterns have changed as a result of the introduction of Roche's Herceptin for HER2-positive breast cancer and Pfizer's Ibrance for hormone receptor-positive breast cancer.

Additionally, the adoption of revolutionary technologies for breast cancer diagnostics has also been supported by medical imaging businesses like GE Healthcare and Hologic.

  • Their 3D and digital mammography devices have raised the standard for breast cancer screening by improving diagnostic precision and early detection.

In the area of diagnostic segments and radiation therapy, the competition is moving forward as these segments have empowered all market players to make informed decisions about their healthcare solutions and allowed healthcare providers to tailor treatment strategies more effectively.

  • Companies like Varian and Accuray, provide cutting-edge emerging solutions like Proton Therapy and Intraoperative Radiation Therapy (IORT). These innovations lessen radiation treatment-related collateral damage to healthy tissues, enhancing patient outcomes and minimizing side effects.
  • Diagnostic laboratories like Quest Diagnostics and LabCorp have expanded genetic testing services, providing comprehensive assessments of breast cancer risk.

Moreover, Research institutions, exemplified by Dana-Farber Cancer Institute and MD Anderson Cancer Center, are at the forefront of breast cancer research. They conduct groundbreaking clinical trials, explore novel therapies, and contribute to our understanding of the disease's biology, driving progress in diagnosis and treatment.

In summary, market players in the breast cancer market are key drivers of progress, with their research, innovation, and strategic partnerships shaping the competitive landscape. Their contributions continue to improve early detection, treatment options, and patient care, ultimately benefiting breast cancer patients worldwide.

Regulatory Framework Analysis

Because of the widespread concern over breast cancer, regulatory bodies frequently work together to establish uniform standards and guidelines. For the breast cancer market to have safe and effective treatments, diagnostics, and devices, regulatory framework advancement is essential. These rules aim to protect patient health, encourage innovation, and give market participants clear factors.

The WHO Global Breast Cancer Initiative (GBCI) aims to prevent 2.5 million breast cancer deaths worldwide between 2020 and 2040 by reducing global breast cancer mortality by 2.5% annually. Regulatory frameworks developed for the breast cancer market include the following significant elements:

  • In order to advance digital health technologies, including those for breast cancer, the U.S. Food and Drug Administration (FDA) has released regulations and guidance documents. In 2020, the FDA issued a final rule on the De Novo classification process for medical devices, which includes breast cancer diagnostic tools. Additionally, the FDA released guidelines for clinical decision support software, which have an effect on the usage of AI-powered breast cancer detection tools.
  • Clinical practice guidelines for the care of breast cancer are routinely updated by the National Comprehensive Cancer Network (NCCN). Updates to the NCCN's guidelines for genetic testing and adjuvant systemic therapy were included in 2020.
  • In 2021, updates included recommendations on the management of HER2-positive breast cancer and systemic therapy options.
  • In 2020, Sacituzumab Govitecan (Trodelvy) received accelerated approval for the treatment of metastatic triple-negative breast cancer. Additionally, Tucatinib (Tukysa) gained FDA approval in 2020 for HER2-positive metastatic breast cancer, and Fam-trastuzumab deruxtecan-nxki (Enhertu) was approved in 2019 and continued to be used in HER2-positive breast cancer treatment.

Clinical Trial Assessment

Many market players actively participate in breast cancer clinical trials, exploring new drug candidates, combination therapies, and innovative treatment approaches.

Phase 1

Phase 2

Phase 3

Phase 4

Pilot Study Evaluating the Uptake of [18F] F-GLN by PET/CT in Breast Cancer

A Phase II Study of NirAparib, Dostarlimab and Radiotherapy in Metastatic, PD-L1 Negative or Immunotherapy-Refractory Triple-Negative Breast Cancer (NADiR)

A Randomized, Multicenter, Parallel, Phase III Open-label Study of the Efficacy and Safety of Hemay022 + AI in Patients With ER+/HER2+ Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy

Clinical Study of Huaier Granule on Reducing the Level of Tumor Markers in Patients with Early-stage Breast Cancer

An Open-Label, Multi-Center, Phase I Study I Study to Evaluate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamics and Anti-tumor Activity of Tetra-specific Antibody GNC-035 in Participants with Locally Advanced or Metastatic Breast Cancer

Exercise in Metastatic Breast Cancer: EMBody

A Non-inferior, Randomized Controlled Phase III Clinical Study Comparing the Efficacy of TCbHPand ECHP-THP in Neoadjuvant Treatment of Operable HER2-positive Breast Cancer

A Prospective, Open-label Study to Evaluate Injectable Albumin-bound Paclitaxel Versus Docetaxel for the Neoadjuvant Treatment of Breast Cancer

A Pilot Trial of Topical Calcipotriene Treatment for Breast Cancer Immunoprevention

Pyrotinib Combined with Trastuzumab, Dalpiciclibe, and Letrozole for HR+/HER2+ Breast Cancer: A Single Arm, Open Label, Phase II Trial

A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of GB491 in Combination with Letrozole in Subjects with HR Positive and HER2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received Systemic Therapy in This Disease Setting

A Prospective, Open-label, Non-inferiority Study to Evaluate Injectable Albumin-bound Paclitaxel Versus Docetaxel for the Adjuvant Treatment of Breast Cancer

Phase 1 Dose-Escalation, Dose-Expansion Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells Injections for the Treatment of Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)

Evaluation of Talazoparib, a PARP Inhibitor, in Patients with Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Survival Benefits of Statins in Breast Cancer Patients with Abnormal Lipid Metabolism

Phase IV Single-arm Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients with Breast Cancer

Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients with Chest-wall and Locally Advanced Breast Cancer

Phase II Study of CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination with Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer (LEADER).

A Non-Inferiority Randomized Multicenter Phase III Trial of Axillary Node Dissection Versus No Axillary Node Dissection in Case of Positive Sentinel Lymph Node in Invasive Breast Cancer

A Randomised, Multicentre Trial Evaluating Harms and Benefits of Endocrine Therapy in Patients ≥70 Years of Age with Lower Risk Breast Cancer (REaCT-70)

Feasibility of Preoperative Radiotherapy in T3 and T4 Breast Cancer Patients Who Are Responders to Neoadjuvant Chemotherapy to Allow for Immediate Reconstruction: A Prospective Study

A Doublelet Metronomic Chemotherapeutic Regimen with Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer Patients: A Monocentric Retrospective Study in China

Delayed Versus Immediate Use of Zoledronic Acid for Postmenopausal Patients With ER/PR Positive Early Breast Cancer Who Are Using Adjuvant Letrozole

Albumin-bound Paclitaxel Combined with Carboplatin Versus Epirubicin Combined with Docetaxel as Neoadjuvant Therapy for Triple-negative Breast Cancer: a Multicenter Randomized Controlled Phase IV Clinical Trial



In conclusion, the market for breast cancer diagnostics and treatments continues to grow significantly and has great potential for industry participants. The environment is favorable for market players and for development because of improvements in early detection technology, individualized treatment strategies, and increased research into novel medicines.

DiseaseLandscape Insights (DLI) is ready to offer a wide range of strategic services to all our stakeholders. Services with a wide range that includes conducting market research and analysis to identify trends and opportunities

The breast cancer market is a dynamic space with enormous potential for innovation and positive influence on the lives of individuals impacted by Cancer.

So, Overall, DLI information enables all manufacturers to conduct in-depth research and development. We help clients to recognize market dynamics, supply chain analysis, and collaborations. Additionally, healthcare businesses gain a competitive edge, improve patient outcomes, and actively support the evolution of international healthcare standards by utilizing our knowledge and expertise.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape